Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.34 |
| ▸ | CA12 | O43570 | 4/20 | 0.34 |
| ▸ | CA9 | Q16790 | 4/20 | 0.34 |
| ▸ | DRD2 | P14416 | 2/20 | 0.34 |
| ▸ | DRD3 | P35462 | 2/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.33 |
| ▸ | PREP | P48147 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | ACHE | P22303 | 2/20 | 0.31 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL225179 | 0.96 | DRD2 (0.41) | CA1DRD2DRD3CYP19A1CA2 | |
| SCHEMBL31683678 | 0.96 | DRD2 (0.41) | CA1DRD2DRD3CYP19A1CA2 | |
| SCHEMBL227778 | 0.89 | DRD2 (0.38) | CA1DRD2DRD3CYP19A1CA2 | |
| SCHEMBL226147 | 0.81 | DRD2 (0.52) | CA1DRD2DRD3CYP19A1CA2 | |
| SCHEMBL226103 | 0.81 | DRD2 (0.39) | CA1DRD2DRD3CYP19A1CA2 | |
| SCHEMBL2001983 | 0.81 | CYP19A1 (0.42) | CA1CA12CA9DRD2DRD3 | |
| SCHEMBL226102 | 0.80 | CYP19A1 (0.39) | CA1DRD2DRD3CYP19A1CA2 | |
| SCHEMBL226101 | 0.79 | DRD2 (0.41) | CA1DRD2DRD3CYP19A1CA2 | |
| SCHEMBL227938 | 0.76 | DRD2 (0.60) | CA1DRD2DRD3CYP19A1CA2 | |
| SCHEMBL6420886 | 0.75 | CYP19A1 (0.38) | CA1CA12CA9DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325930-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATOR | RADIUS HEALTH, INC. | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325930-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATOR | ESR1, GPER1, ESR2 | CA1 304/4885CA12 955/4885CA9 1880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.